Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats

Hypertension

Volumn 35, Issue 6, 2000, Pages 1221-1225

  Intengan, Hope D ^a   Schiffrin, Ernesto L ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Angiotensin converting enzyme; Hypertension, malignant; Natriuretic peptides; Rats, stroke prone SHR; Remodeling; Vasculature

Indexed keywords

OMAPATRILAT;

ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; DRUG EFFECT; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE; VASCULAR RESISTANCE;

EID: 0034130979     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.35.6.1221     Document Type: Article

References (41)

1. Robl JA, Sun CQ, Stevenson J, Ryono DE, Simpkins LM, Cimarusti MP, Dejneka T, Slusarchyk WA, Chao S, Stratton L, Misra RN, Bednarz MS, Asaad MM, Cheung HS, Abboa-Offei BE, Smith PL, Mathers PD, Fox M, Schaeffer TR, Seymour AA, Trippodo NC. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem. 1997;40:1570-1577.
2. Traub O, Lloyd MC, Webb RC. Long-term effects of brief antihypertensive treatment on systolic blood pressure and vascular reactivity in young genetically hypertensive rats. Cardiovasc Drugs Ther. 1995;9: 421-429.
3. Jablonskis LT, Rogers PF, Lungershausen YK, Howe PR. Chronic central administration of enalaprilat lowers blood pressure in stroke-prone spontaneously hypertensive rats. J Auton Nerv Syst. 1992;39:119-126.
4. Krieger EM, Yamori Y, Lovenberg WM. Angiotensin converting activity assessed in vivo is increased in hereditary hypertensive rats. Braz J Med Biol Res. 1992;25:1215-1222.
5. Margolius HS. Kallikreins and kinins: some unanswered questions about system characteristics and roles in human disease. Hypertension. 1995; 26:221-229.
6. Gohlke P, Unger T. Chronic low-dose treatment with perindopril improves cardiac function in stroke-prone spontaneously hypertensive rats by potentiation of endogenous bradykinin. Am J Cardiol. 1995;76: 41E-45E.
7. Nishimura Y, Suzuki A. Relaxant effects of vasodilator peptides on isolated basilar arteries from stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1997;24:157-161.
8. Morii N, Nakao K, Kihara M, Sugawara A, Sakamoto M, Yamori Y, Imura H. Decreased content in left atrium and increased plasma concentration of atrial natriuretic polypeptide in spontaneously hypertensive rats (SHR) and SHR stroke-prone. Biochem Biophys Res Commun. 1986; 135; 74-81.
9. Kato J, Kida O, Nakamura S, Sasaki A, Kodama K, Tanaka K. Atrial natriuretic polypeptide (ANP) in the development of spontaneously hypertensive rats (SHR) and stroke-prone SHR (SHRSP). Biochem Biophys Res Commun. 1987;143:316-322.
10. Goto M, Itoh H, Tanaka I, Suga S, Ogawa Y, Kishimoto I, Nakagawa M, Sugawara A, Yoshimasa T, Mukoyama M, Nakao K. Altered gene expression of natriuretic peptide receptor subtypes in the kidney of stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1995;22(suppl 1):S177-S179.
11. Pham I, Gonzalez W, el Amrani AI, Fournie-Zaluski MC, Philippe M, Laboulandine I, Roques BP, Michel JB. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. J Pharmacol Exp Ther. 1993;265: 1339-1347.
12. Seymour AA, Swerdel JN, Abboa-Offei B. Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme. J Cardiovasc Pharmacol. 1991;17:456-465.
13. Deng LY, Li JS, Schiffrin EL. Endothelium-dependent relaxation of small arteries from essential hypertensive patients: mechanisms and comparison with normotensive subjects and with responses of vessels from spontaneously hypertensive rats. Clin Sci. 1995;88:611-622.
14. Falloon BJ, Bund SJ, Tulip JR, Heagerty AM. In vitro perfusion studies of resistance artery function in genetic hypertension. Hypertension. 1993; 22:486-495.
15. Laurant P, Touyz RM, Schiffrin EL. Effect of pressurization on mechanical properties of mesenteric small arteries from spontaneously hypertensive rats. J Vasc Res. 1997;34:117-125.
16. Schiffrin EL, Hayoz D. How to assess vascular remodeling in small and medium-sized muscular arteries in humans. J Hypertens. 1997;15: 571-584.
17. Trippodo NC, Robl JA, Asaad MM, Fox M, Panchal BC, Schaeffer TR. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens. 1998;11:363-372.
18. French JF, Anderson BA, Downs TR, Dage RC. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension. J Cardiovasc Pharmacol. 1995;26:107-113.
19. Massien C, Azizi M, Guyene TT, Vesterqvist O, Mangold B, Menard J. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans. Clin Pharmacol Ther. 1999;65:448-459.
20. Favrat B, Burnier M, Nussberger J, Lecomte JM, Brouard R, Waeber B, Brunner HR. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J Hypertens. 1995;13: 797-804.
21. Burnett JC Jr. Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens. 1999;17:S37-S43.
22. Hashimoto Y, Kurosawa Y, Minami K, Fushimi K, Narita H. A novel angiotensin II-receptor antagonist, 606A, induces regression of cardiac hypertrophy, augments endothelium-dependent relaxation and improves renal function in stroke-prone spontaneously hypertensive rats. Jpn J Pharmacol 1998;76:185-192.
23. Novosel D, Lang MG, Noll G, Luscher TF. Endothelial dysfunction in aorta of the spontaneously hypertensive, stroke-prone rat: effects of therapy with verapamil and trandolapril alone and in combination. J Cardiovasc Pharmacol. 1994;24:979-985.
24. Yang ST, Faraci FM, Heistad DD. Effects of cilazapril on cerebral vasodilatation in hypertensive rats. Hypertension. 1993;22:150-155.
25. Igaki T, Itoh H, Suga S, Komatsu Y, Ogawa Y, Doi K, Yoshimasa T, Nakao K. Insulin suppresses endothelial secretion of C-type natriuretic peptide, a novel endothelium-derived relaxing peptide. Diabetes. 1996; 45(suppl 3):S62-S64.
26. Wright RS, Wei CM, Kim CH, Kinoshita M, Matsuda Y, Aarhus LL, Burnett JC Jr, Miller WL. C-type natriuretic peptide-mediated coronary vasodilation: role of the coronary nitric oxide and particulate guanylate cyclase systems. J Am Coll Cardiol. 1996;28:1031-1038.
27. Kahonen M, Makynen H, Wu X, Arvola P, Porsti I. Endothelial function in spontaneously hypertensive rats: influence of quinapril treatment. Br J Pharmacol. 1995;115:859-867.
28. Intengan HD, Thibault G, Li JS, Schiffrin EL. Resistance artery mechanics, structure, and extracellular components in spontaneously hypertensive rats: effects of angiotensin receptor antagonism and converting enzyme inhibition. Circulation. 1999;100:2267-2275.
29. Sharifi AM, Li JS, Endemann D, Schiffrin EL. Effects of enalapril and amlodipine on small artery structure and composition, and on endothelial dysfunction in spontaneously hypertensive rats. J Hypertens. 1998; 16: 457-466.
30. 1 angiotensin-receptor blockade on structure and function of small arteries in SHR. J Cardiovasc Pharmacol. 1997;30:75-83.
31. McDowell G, Coutie W, Shaw C, Buchanan KD, Struthers AD, Nicholls DP. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmacol. 1997;43:329-332.
32. Chillon JM, Heistad DD, Baumbach GL. Effects of endothelin receptor inhibition on cerebral arterioles in hypertensive rats. Hypertension. 1996; 27:794-798.
33. Sharifi AM, He G, Touyz RM, Schiffrin EL. Vascular endothelin-1 expression and effect of an endothelin ETA antagonist on structure and function of small arteries from stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1998;31(suppl 1):S309-S312.
34. Winter RJ, Zhao L, Krausz T, Hughes JM. Neutral endopeptidase 24.11 inhibition reduces pulmonary vascular remodeling in rats exposed to chronic hypoxia. Am Rev Respir Dis. 1991;133:1342-1346.
35. Itoh H, Pratt Re, Dzau VJ. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest. 1990;86: 1690-1697.
36. Marumo T, Nakaki T, Hishikawa K, Hirahashi J, Suzuki H, Kato R, Saruta T. Natriuretic peptide-augmented induction of nitric oxide synthase through cyclic guanosine 3′,5′-monophosphate elevation in vascular smooth muscle cells. Endocrinology. 1995;136:2135-2142.
37. Itoh H, Nakao K. Antagonism between the vascular renin-angiotensin and natriuretic peptide systems in vascular remodelling. Blood Press Suppl. 1994;5:49-53.
38. Li JS, Schiffrin EL. Chronic endothelin receptor antagonist treatment of young spontaneously hypertensive rats. J Hypertens. 1995;13:647-652.
39. Li JS, Schiffrin EL. Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist. Hypertension. 1995;25:495-500.
40. Li JS, Schiffrin EL. Effect of short-term treatment of SHR with the novel calcium channel antagonist mibefradil on function of small arteries. Am J Hypertens. 1997;10:94-100.
41. Schiffrin EL, Deng LY, Larochelle P. Effects of a β-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension. 1994;23:83-91.